arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Minerva Neurosciences, Inc.

NERV
$2.29 ▼ -0.24 (-9.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Minerva Neurosciences, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $106.7M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC 3.9% ↘
FCF / Share $-0.29 ↘
Trailing P/E 6.4x
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-125.40M
↓ -3241.5% —
FCF / Share Free cash flow per share
$-0.29
↓ -131.7% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↑
100
Cash Quality ↓
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 55 quarters